High‐definition transcranial direct current stimulation—An open‐label pilot intervention in alleviating depressive symptoms and cognitive deficits in late‐life depression

• Published in: CNS neuroscience & therapeutics 2019-11, Vol.25 (11), p.1244-1253
• Main Authors: Wong, Hau‐lam, Chan, Wai Chi, Wong, Yiu‐lung, Wong, Sze‐nga, Yung, Hui‐yan, Wong, Sau‐man Corine, Cheng, Pak‐wing Calvin
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Ambulatory Care Facilities - trends; Antidepressive Agents - administration & dosage; cognitive dysfunction; Cognitive Dysfunction - diagnosis; Cognitive Dysfunction - psychology; Cognitive Dysfunction - therapy; Combined Modality Therapy - methods; Combined Modality Therapy - trends; depression; Depression - diagnosis; Depression - psychology; Depression - therapy; Female; Humans; Male; Original; Pilot Projects; transcranial direct current stimulation; Transcranial Direct Current Stimulation - methods; Transcranial Direct Current Stimulation - trends
• ISSN: 1755-5930; 1755-5949
• DOI: 10.1111/cns.13253

The efficacy of high‐definition transcranial direct current stimulation (HD‐tDCS) in late‐life depression (LLD) remains unknown due to limited research on its therapeutic effects on the hallmarks of LLD—the depressive and cognitive symptoms. The present open‐label pilot study aimed to examine the effectiveness of HD‐tDCS as an augmentation therapy with antidepressants in improving the depressive and cognitive symptoms for LLD. Significant improvements were hypothesized in the depressive, cognitive, and daily functioning outcomes over time. A total of 15 subjects with LLD (13 females, mean age = 73.27 ± 6.25) received five consecutive daily sessions of 20‐minute active HD‐tDCS interventions weekly for 2 weeks, with a 2 mA anodal stimulation over F3 and cathodal stimulation over FC1, AF3, F7, and FC5. Depressive symptoms and cognitive and daily functioning were assessed across five assessment timepoints. The results revealed that the HD‐tDCS was effective in reducing the depressive severity and the remission rates, with a sustained effect at both the 1‐month and 3‐month follow‐up. Pre‐post improvements were seen in the overall cognitive functioning and in verbal fluency, but not in executive functioning. Our pilot study provides a preliminary result of HD‐tDCS in LLD, which was a safe and effective treatment in alleviating depressive symptoms, with mild cognitive improvements observed. Further larger scale randomized controlled trials are needed to confirm this result.